Il ruolo degli enti regolatori nei servizi sanitari e nell'assistenza agli anziani

Translated title of the contribution: The role of regulatory agencies in health services and elderly care

Research output: Contribution to journalArticle

Abstract

The population older than 60 years is growing faster than any other age group, as a result of longer life expectancy and declining fertility rates. Although population aging is a marker of the success of public health policies, it also challenges the established way of implementing such policies, which require a new strategic approach. Taking into account current achievements in this field, regulatory agencies should undertake additional efforts to ensure that the needs of older persons are taken into account in the development and evaluation of new medicines, to improve our understanding of best methodologies to evaluate the benefit-risk ratio for usage of medications in older patients. Health professionals need to be ensured that the use of newly approved medicines in the intended population is supported by relevant data on the benefit-risk balance. A representative population of patients must cover the whole age range when studied in the preauthorization phase. Another need is the improvement of available information to patients and prescribers, to support safer use of medications. During drug development, a dialogue with regulators should be held to be sure older people needs will be taken into consideration. Collection of data from all possible sources should be optimized, to avoid underreported adverse events in elderly people.

Original languageItalian
JournalGiornale Italiano di Cardiologia
Volume14
Issue number3 SUPPL1
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Health Services for the Aged
Population
Patient Advocacy
Birth Rate
Public Policy
Health Policy
Life Expectancy
Public Health
Age Groups
Odds Ratio
Health
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{a2ba8e89f4e34ab280959e2a3822a1c3,
title = "Il ruolo degli enti regolatori nei servizi sanitari e nell'assistenza agli anziani",
abstract = "The population older than 60 years is growing faster than any other age group, as a result of longer life expectancy and declining fertility rates. Although population aging is a marker of the success of public health policies, it also challenges the established way of implementing such policies, which require a new strategic approach. Taking into account current achievements in this field, regulatory agencies should undertake additional efforts to ensure that the needs of older persons are taken into account in the development and evaluation of new medicines, to improve our understanding of best methodologies to evaluate the benefit-risk ratio for usage of medications in older patients. Health professionals need to be ensured that the use of newly approved medicines in the intended population is supported by relevant data on the benefit-risk balance. A representative population of patients must cover the whole age range when studied in the preauthorization phase. Another need is the improvement of available information to patients and prescribers, to support safer use of medications. During drug development, a dialogue with regulators should be held to be sure older people needs will be taken into consideration. Collection of data from all possible sources should be optimized, to avoid underreported adverse events in elderly people.",
keywords = "Drugs, Elderly, Regulatory agency",
author = "Massimo Fini and Maurizio Volterrani",
year = "2013",
month = "3",
doi = "10.1714/1261.13937",
language = "Italian",
volume = "14",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "3 SUPPL1",

}

TY - JOUR

T1 - Il ruolo degli enti regolatori nei servizi sanitari e nell'assistenza agli anziani

AU - Fini, Massimo

AU - Volterrani, Maurizio

PY - 2013/3

Y1 - 2013/3

N2 - The population older than 60 years is growing faster than any other age group, as a result of longer life expectancy and declining fertility rates. Although population aging is a marker of the success of public health policies, it also challenges the established way of implementing such policies, which require a new strategic approach. Taking into account current achievements in this field, regulatory agencies should undertake additional efforts to ensure that the needs of older persons are taken into account in the development and evaluation of new medicines, to improve our understanding of best methodologies to evaluate the benefit-risk ratio for usage of medications in older patients. Health professionals need to be ensured that the use of newly approved medicines in the intended population is supported by relevant data on the benefit-risk balance. A representative population of patients must cover the whole age range when studied in the preauthorization phase. Another need is the improvement of available information to patients and prescribers, to support safer use of medications. During drug development, a dialogue with regulators should be held to be sure older people needs will be taken into consideration. Collection of data from all possible sources should be optimized, to avoid underreported adverse events in elderly people.

AB - The population older than 60 years is growing faster than any other age group, as a result of longer life expectancy and declining fertility rates. Although population aging is a marker of the success of public health policies, it also challenges the established way of implementing such policies, which require a new strategic approach. Taking into account current achievements in this field, regulatory agencies should undertake additional efforts to ensure that the needs of older persons are taken into account in the development and evaluation of new medicines, to improve our understanding of best methodologies to evaluate the benefit-risk ratio for usage of medications in older patients. Health professionals need to be ensured that the use of newly approved medicines in the intended population is supported by relevant data on the benefit-risk balance. A representative population of patients must cover the whole age range when studied in the preauthorization phase. Another need is the improvement of available information to patients and prescribers, to support safer use of medications. During drug development, a dialogue with regulators should be held to be sure older people needs will be taken into consideration. Collection of data from all possible sources should be optimized, to avoid underreported adverse events in elderly people.

KW - Drugs

KW - Elderly

KW - Regulatory agency

UR - http://www.scopus.com/inward/record.url?scp=84877776371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877776371&partnerID=8YFLogxK

U2 - 10.1714/1261.13937

DO - 10.1714/1261.13937

M3 - Articolo

C2 - 23612211

AN - SCOPUS:84877776371

VL - 14

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 3 SUPPL1

ER -